<DOC>
	<DOCNO>NCT02121080</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetic ( PK ) profile , immunogenicity REGN2222 ascend cohort healthy adult volunteer .</brief_summary>
	<brief_title>Study Safety Tolerability REGN2222 ( SAR438584 ) Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . A healthy man woman age 18 60 year 2 . Body mass index 18.0 kg/m2 32.0 kg/m2 , inclusive 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent 1 . Serum hemoglobin , creatinine , alkaline phosphatase , CPK , and/or hepatic enzyme ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] , total bilirubin [ unless investigator evidence increase bilirubin corresponds Gilbert 's type syndrome elevate indirect bilirubin ] ) &gt; 1.5 upper limit normal ( ULN ) , laboratory finding show evidence organ dysfunction clinically significant abnormality normal range , determine investigator screen visit 2 . Use concomitant medication within 30 day least 5 halflives , whichever longer , screen visit , include prescription medication ( except contraceptive ) , nutritional supplement , overthecounter medication ( except acetaminophen ) 3 . Hospitalization reason within 60 day screen visit 4 . History positive human immunodeficiency virus ( HIV ) screen result screen visit 5 . History positive blood test result hepatitis B surface antigen and/or hepatitis C virus antibody screen visit 6 . History autoimmune disease 7 . History respiratory disease ( e.g , asthma , chronic obstructive pulmonary disease ) 8 . History drug alcohol abuse within 1 year prior screen visit 9 . Participation clinical research study evaluate another investigational drug therapy within 30 day , within least 5 halflives , investigational drug ( whichever longer ) prior screen visit 10 . Pregnant breastfeed woman 11 . Sexually active men* woman childbearing potential** unwilling practice adequate contraception study , 3 month last dose study drug ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider childbearing potential . Contraception required woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>